- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06329323
SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours (SUMMER)
The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign OGCT and no ovarian pathology.
The main question[s] it aims to answer are:
- To understand the circulating miRNA expression of malignant ovarian germ cell tumours (MOGCTs) compared to those with benign ovarian germ cell tumours (BOGCTs)
- To understand the imaging profile of MOGCTs compared to that of BOGCTs
- To establish the relationship between serum and plasma miRNA expression in response to treatment and relapse of disease
- To discover if miRNA expression correlates with radiomic features of OGCTs on both ultrasound and MRI
- To see if we can link the micro RNAs in tumour samples to those found in blood samples, and to find a plausible explanation for why these micro RNAs are raised (in terms of the tumour biology itself).aims
Participants will have serial blood tests at different time points in their care to assess how circulating miRNA levels are affected by treatment and/or remission and/or relapse. If they have surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their mass.
Researchers will compare the circulating miRNA profile of patients with a benign ovarian germ cell tumour and no ovarian pathology to see where the differences lie. If a patient with a BOGCT requires surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their benign mass.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Case population (MOGCTs):
- Serum aFP (alpha fetoprotein), hCG (human chorionic gonadotrophin), LDH (lactate dehydrogenase) and Ca125 (cancer antigen 125) tumour markers measured at time of diagnosis
- Additional serum and plasma sample to be obtained at the same time as initial bloods
- Subsequent serum and plasma samples to be obtained as per study arms 1-3 based on cancer staging
- Tissue samples will be obtained at the time of surgery
Control population:
Participants acting as controls will be identified from those attending for TV-USS where either a benign teratoma or no pathology is identified (e.g. from a gynaecology clinic). A total of 26ml of blood will be taken. Serum aFP, hCG, LDH and Ca125 will be measured as per routine clinical practice in patients with a benign OGCT.
Patients in the control population (benign germ cell tumours or patients with no known gynaecological pathology) will have a single blood test for miRNA analysis.
If participants require an operation for the benign GCT, tissue samples will be obtained at the time of surgery.
miRNA analysis will be performed using NanoString for the discovery panel. Further targeted sequencing will be performed in the larger prospective study using specific miRNA panels. This may be done using NanoString or a custom MiRNA assay primer.
Endpoint The pilot will be completed after the final patient has completed 12 months of follow up. The pilot data analysis will take place at that point.
We anticipate that the study will end 12 months after the final participant has completed 24 months of follow up, which gives 12 months for analysis of the samples. The number of participants to take part will be based on a power calculation performed at the time of analysis of the pilot data.
DATA COLLECTION AND MANAGEMENT Patients will enter study arm 1-3 based on cancer staging, or will belong to the control group.
Each participant will be followed up for a maximum of 2 years after they receive their definitive treatment (surgery and/or (neo)adjuvant chemotherapy). We anticipate this will be a maximum of 30 months total time in the study.
An interim analysis of data will be performed at 12 months, with a view to:
- Identify key miRNAs for prospective validation
- Allow for appropriate power calculation of the prospective validation study
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nina C Cooper, MBBS BSc
- Phone Number: 02033513150
- Email: nina.cooper3@nhs.net
Study Contact Backup
- Name: Srdjan Saso, MRCOG Phd
- Phone Number: 02033513150
- Email: srdjan.saso01@imperial.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with a new diagnosis of a malignant ovarian germ cell tumour.
- The control population will include all patients with a new diagnosis of a benign ovarian germ cell tumour or no known gynaecological pathology.
Exclusion Criteria:
- Previous or ongoing chemotherapy for MOGCT
- Previous surgery for MOGCT
- Pregnancy - this will be verbally communicated for those not having surgery or chemotherapy, for those having surgery or chemotherapy a urine pregnancy test should be negative and documented in the clinical notes.
- Fetal circulating DNA is known to be present in maternal blood and therefore pregnant women should not be included in this study
- Denial of informed consent
- Age <16 years
- History of any other cancer
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cases- Malignant Ovarian Germ Cell Tumour - Arm 1
Patients with a diagnosis of stage 1a MOGCT.
Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively
|
Serum and plasma microRNA quantification
Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
|
Cases - Malignant Ovarian Germ Cell Tumour - Arm 2
Patients with a diagnosis of stage 1b/1c MOGCT.
Bloods taken at the following time points: Day 0, then 4 weeks; 6 months; 12 months; 24 months post-operatively OR post-final dose of adjuvant chemotherapy
|
Serum and plasma microRNA quantification
Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
|
Cases - Malignant Ovarian Germ Cell Tumour - Arm 3
Patients with a diagnosis of stage 2 or higher MOGCT.
Bloods taken at the following time points: Day 0, then 4 weeks post-neoadjuvant chemotherapy, then 4 weeks; 6 months; 12 months; 24 months post-operatively
|
Serum and plasma microRNA quantification
Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
|
Controls - Benign Ovarian Germ Cell Tumour
Bloods taken at the time of diagnosis of BOGCT (single blood test)
|
Serum and plasma microRNA quantification
Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
|
Controls - No Known Gynaecological Pathology
Single blood test
|
Serum and plasma microRNA quantification
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in microRNA expression (plasma) between benign and malignant masses
Time Frame: 24 months
|
Comparison of heatmaps based on mean expression of clusters across samples
|
24 months
|
Difference in microRNA expression (serum) between benign and malignant masses
Time Frame: 24 months
|
Comparison of heatmaps based on mean expression of clusters across samples
|
24 months
|
microRNA expression (plasma)
Time Frame: 24 months
|
Differential expression of microRNAs (assessed using a moderated t statistic and P values adjusted for multiple testing)
|
24 months
|
microRNA expression (serum)
Time Frame: 24 months
|
Differential expression of microRNAs (assessed using a moderated t statistic and P values adjusted for multiple testing)
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative measure of circulating miRNA before treatment
Time Frame: 24 months
|
miRNA expression in plasma samples of women with a diagnosis of a MOGCT compared to those of women with BOGCTs using nCounter miRNA Expression panels
|
24 months
|
Quantitative measure of circulating miRNA after treatment
Time Frame: 24 months
|
miRNA expression in serum samples of women with a diagnosis of a MOGCT compared to those of women with BOGCTs using nCounter miRNA Expression panels
|
24 months
|
Quantitative measure of circulating miRNA after treatment
Time Frame: 24 months
|
miRNA expression in plasma samples of women with a diagnosis of a MOGCT compared to those of women with BOGCTs using nCounter miRNA Expression panels
|
24 months
|
Performance of segmentation model on ultrasound images
Time Frame: 24 months
|
Correlation between identification of region of interest (ROI) to examiner segmentation.
Dice surface coefficient (DICE).
|
24 months
|
Performance of segmentation model on MRI images
Time Frame: 24 months
|
Correlation between identification of region of interest (ROI) to examiner segmentation.
Dice surface coefficient (DICE)
|
24 months
|
Performance of classification model on ultrasound images
Time Frame: 24 months
|
Correlation between benign or malignant diagnosis by model vs ultrasound subjective assessment or histopathological diagnosis (area under the ROC curve (AUC), F1-score)
|
24 months
|
Performance of classification model on MRI images
Time Frame: 24 months
|
Correlation between benign or malignant diagnosis by model vs ultrasound subjective assessment or histopathological diagnosis (area under the ROC curve (AUC), F1-score)
|
24 months
|
Quantitative measure of circulating miRNA before treatment
Time Frame: 24 months
|
miRNA expression in serum samples of women with a diagnosis of a MOGCT compared to those of women with BOGCTs using nCounter miRNA Expression panels
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Srdjan Saso, PhD MRCOG MRCS, Imperial College Healthcare NHS Trust
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- 23CX8477
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Neoplasms
-
Roswell Park Cancer InstituteCompletedFallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IIA Ovarian Cancer | Stage IIB Ovarian Cancer | Stage IIC Ovarian Cancer | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian Cancer | Stage IA Ovarian Cancer | Stage IB Ovarian Cancer | Stage IC... and other conditionsUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Ovarian Carcinoma | Ovarian Neoplasm | Ovarian Clear Cell Tumor | Adnexal Mass | Ovarian Endometrioid Tumor | Ovarian Serous Tumor | Borderline Ovarian Epithelial TumorUnited States
-
Maastricht University Medical CenterVieCuri Medical Centre; Orbis Medical Centre; St.Jans Gasthuis Weert; Laurentius...TerminatedOvarian Cancer | Ovarian Carcinoma | Ovarian Cyst | Ovarian MassNetherlands
-
Health Science Center of Xi'an Jiaotong UniversityRecruitingOvarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, OvarianChina
-
University of WashingtonNational Cancer Institute (NCI)CompletedCaregiver | Stage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
Centre Leon BerardCancer Côte d'or registry; Cancer Calvados registryUnknownOvarian Epithelial CancerFrance
-
GlaxoSmithKlineCompletedNeoplasms, OvarianUnited States
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Seoul National University HospitalSamsung Medical Center; Takeda; Asan Medical Center; Yonsei UniversityNot yet recruitingOvarian Cancer | Epithelial Ovarian Cancer | Ovarian Cancer Stage IV | Ovarian Cancer Stage III
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCancer Survivor | Stage IIIA Ovarian Epithelial Cancer | Stage IIIB Ovarian Epithelial Cancer | Stage IIIC Ovarian Epithelial Cancer | Stage IIA Ovarian Epithelial Cancer | Stage IIB Ovarian Epithelial Cancer | Stage IIC Ovarian Epithelial Cancer | Stage IA Ovarian Epithelial Cancer | Stage IB Ovarian... and other conditionsUnited States
Clinical Trials on Blood test
-
French National Agency for Research on AIDS and...Completed
-
Pascual Gregori RoigHospital Universitario de la Plana; FUNDACIÓN DAVALOS FLETCHERCompletedHyperbilirubinemia, Neonatal | Anemia Neonatal | Polycythemia SecondarySpain
-
Wingate InstituteTel Aviv UniversityCompleted
-
University Hospital, ToursCompleted
-
Cairo UniversityUnknownClass III Malocclusion | Class II Malocclusion
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia | Pulmonary Arteriovenous MalformationsUnited Kingdom
-
University Hospital, MontpellierNot yet recruiting
-
Minovia Therapeutics Ltd.RecruitingMyelodysplastic SyndromesIsrael
-
Centre Hospitalier Universitaire de NīmesRecruitingNeoplasm Metastasis | Colorectal Cancer | Disseminated CancerFrance